Killing of Fas ligand-resistant renal carcinoma cells by interleukin-2-and BCG-activated effector cells

被引:7
作者
Brandau, S
Suttmann, H
Flad, HD
Jocham, D
Böhle, A
机构
[1] Med Univ Lubeck, Dept Urol, D-23538 Lubeck, Germany
[2] Res Ctr, Dept Immunol & Cell Biol, Borstel, Germany
关键词
renal cell carcinoma; immunotherapy; perforin; IL-2; bacillus Calmette-Guerin;
D O I
10.1007/s002620000118
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activated cytolytic effector cells like lymphokine-activated killer (LAK) and the recently described bacillus-Calmette-C ui rin-activated killer (BAK) cells are thought to mediate antitumor effects against metastatic renal cell carcinoma (RCC) and superficial bladder cancer respectively, Perforin and Fas ligand (FasL) have been described as the major lytic principles in cellular cytotoxicity. Using a radioactive-release assay and specific inhibitors, we investigated the molecular mechanisms used by LAK and BAK cells in the Lysis of renal carcinoma cells. In addition, we evaluated the susceptibility of RCC cells to FasL-mediated cytotoxicity. LAK and BAK cells effectively lysed the renal cancer cell line SK-RC-35 upon cell-cell contact. Both effector cell populations were shown to produce perforin and Fast as determined by reverse transcriptase/polymerase chain reaction RT-PCR. Using fluorescence-activated cell sorting analyses and RT-PCR, we detected a marked Fas receptor (Fas, CD95) expression on RCC cells. However, RCC cells were shown to be resistant to killing by recombinant Fast rind lysis by BAK and LAK cells was not inhibited in the presence of anti-FasL antibody. In contrast, the cytotoxicity exerted by LAK and BAK cells was drastically reduced ill the presence of the Ca2(+)- chelating agent EGTA as well as concanamycin A, a specific inhibitor of perforin-mediated lysis. These results demonstrate that cytolysis of Fast-resistant RCC cells by activated immune cells is mediated via perforin. Our findings give Further insights into the molecular mechanisms involved in the elimination of RCC by cytotoxic lymphocytes activated with biological response modifiers.
引用
收藏
页码:369 / 376
页数:8
相关论文
共 52 条
  • [1] ANTI-TUMOR REACTIVITY OF HUMAN LYMPHOKINE ACTIVATED KILLER (LAK) CELLS AGAINST FRESH AND CULTURED PREPARATIONS OF RENAL-CELL CANCER
    BELLDEGRUN, A
    UPPENKAMP, I
    ROSENBERG, SA
    [J]. JOURNAL OF UROLOGY, 1988, 139 (01) : 150 - 155
  • [2] FREQUENCY OF EFFECTOR CELLS IN POPULATIONS CONTAINING CYTOTOXIC T-LYMPHOCYTES
    BERKE, G
    GABISON, D
    FELDMAN, M
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1975, 5 (12) : 813 - 818
  • [3] EFFECTS OF LOCAL BACILLUS CALMETTE-GUERIN THERAPY IN PATIENTS WITH BLADDER-CARCINOMA ON IMMUNOCOMPETENT CELLS OF THE BLADDER WALL
    BOHLE, A
    GERDES, J
    ULMER, AJ
    HOFSTETTER, AG
    FLAD, HD
    [J]. JOURNAL OF UROLOGY, 1990, 144 (01) : 53 - 58
  • [4] Boonstra JG, 1997, J AM SOC NEPHROL, V8, P1517
  • [5] de Landazuri M O, 1972, Nat New Biol, V238, P18
  • [6] THE TREATMENT OF RENAL-CELL CARCINOMA WITH HUMAN-LEUKOCYTE ALPHA-INTERFERON
    DEKERNION, JB
    SARNA, G
    FIGLIN, R
    LINDNER, A
    SMITH, RB
    [J]. JOURNAL OF UROLOGY, 1983, 130 (06) : 1063 - 1066
  • [7] EBERT T, 1990, CANCER RES, V50, P5531
  • [8] Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells
    Friesen, C
    Fulda, S
    Debatin, KM
    [J]. LEUKEMIA, 1997, 11 (11) : 1833 - 1841
  • [9] Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
    Friesen, C
    Herr, I
    Krammer, PH
    Debatin, KM
    [J]. NATURE MEDICINE, 1996, 2 (05) : 574 - 577
  • [10] RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY
    FYFE, G
    FISHER, RI
    ROSENBERG, SA
    SZNOL, M
    PARKINSON, DR
    LOUIE, AC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) : 688 - 696